sur Quantum Biopharma Ltd.
Quantum Biopharma Faces Class Action Lawsuit Over Alleged Stock Manipulation
Quantum BioPharma Ltd., a biopharmaceutical company listed on NASDAQ, is involved in a class action lawsuit initiated by shareholder Paul Durkacz. The legal action accuses the Canadian banks, CIBC and RBC, of illegally manipulating the company's stock between January 2021 and October 2025. This alleged manipulation has reportedly harmed shareholders materially.
Quantum BioPharma is seeking to become a lead plaintiff to protect its investors. The company's core focus includes developing treatments for neurodegenerative and metabolic disorders, particularly through its subsidiary Lucid Psycheceuticals Inc. Despite ongoing litigation, Quantum BioPharma continues its strategic investments and product development initiatives.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Quantum Biopharma Ltd.